TCRX Stock Analysis: Buy, Sell, or Hold?
TCRX - TScan Therapeutics, Inc. Common Stock
$1.26
0.05 (4.13%)
▲
5d:
+3.28%
30d:
+18.87%
90d:
+22.33%
BUY
MODERATE Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 05, 2026
0d
Get Alerted When TCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called TCRX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TCRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: TCRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TCRX is currently trading at $1.26, which is considered slightly high relative to its 30-day fair value range of $1.04 to $1.26.
Technical Outlook: Technically, TCRX is in a uptrend. Immediate support is located at $1.13, while resistance sits at $1.35. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+376.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TCRX is in a uptrend. Immediate support is located at $1.13, while resistance sits at $1.35. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+376.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.04 -
$1.26
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 376.2% below Wall St target ($6.00)
Trading Range Analysis
30-Day Trading Range
$1.04 -
$1.26
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.13
Resistance Level
$1.36
Current Trend
Uptrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.60
Wall Street Target
$6.00
(+376.2%)
Revenue Growth (YoY)
286.0%
Share & Embed Analysis
Last updated: May 08, 2026 6:09 PM ET
Data refreshes hourly during market hours. Next update: 7:09 PM
Data refreshes hourly during market hours. Next update: 7:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TCRX showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Lynx1 Capital Management…
BUY
6232 shares
2025-12-23
Lynx1 Capital Management…
BUY
75500 shares
2025-12-22
Lynx1 Capital Management…
BUY
80069 shares
2025-12-19
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$408 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$230 | 55 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 58 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$27 | 56 HOLD |
